Amylin-Based Drugs Show Striking Weight Loss and Diabetes Remission in New Trials
A new review in Diabetes Therapy finds that three amylin-based agonists—zenagamtide, eloralintide and CagriSema—deliver unprecedented weight loss and, in some ...
A new review in Diabetes Therapy finds that three amylin-based agonists—zenagamtide, eloralintide and CagriSema—deliver unprecedented weight loss and, in some ...
A new online study shows that asking GLP-1RA users to photograph their medications is feasible and reveals that most compounded ...
A new review maps how the gut hormones behind blockbuster weight-loss drugs may also influence PCOS, endometriosis and gynaecological cancers.
As powerful new weight-loss drugs transform obesity treatment, leading surgeons argue that metabolic bariatric surgery remains an essential, durable component ...
A new EASO position statement argues that Europe's health systems must be restructured around five pillars to deliver the benefits ...
A nine-site U.S. cohort study found that GLP-1 receptor agonists produced roughly four times more weight loss than SGLT2 inhibitors ...
A large real-world study finds once-weekly semaglutide outperforms sulfonylureas, DPP4 inhibitors, and thiazolidinediones on blood sugar, weight, blood pressure, and ...
The first systematic review and meta-analysis of GLP-1 receptor agonist use in body contouring surgery finds a possible wound dehiscence ...
A retrospective study from the University of Palermo links type 2 diabetes to worse hearing thresholds and finds that GLP-1 ...
A meta-analysis of 19 high-potency incretin trials finds that objective signs of malnutrition and lean mass loss occur far more ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine